Trazodone half-life
The seven-hour curve represents the later parent-trazodone elimination phase described in labeling context.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Trazodone: evidence and interpretation notes
Parent compound and treatment context
The seven-hour curve represents the later parent-trazodone elimination phase described in labeling context. Biphasic decline and the active mCPP metabolite mean that one line cannot describe every portion of exposure.
A 7-hour input gives this profile one auditable line for Trazodone. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Trazodone often needs steady-state and metabolite context, especially when doses repeat. This single-dose curve helps compare elimination speed but does not model treatment response, discontinuation symptoms, or medication changes.
What each source contributes
- DailyMed: TRAZODONE HYDROCHLORIDE TABLET [REMEDYREPACK INC.]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Trazodone. This identity record confirms names and compound identity and does not supply a human half-life.
- Pharmacokinetics of Trazodone in Hispaniolan Parrots (Amazona ventralis). This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Trazodone, the numerical model is tied most closely to DailyMed: TRAZODONE HYDROCHLORIDE TABLET [REMEDYREPACK INC.]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The 6-to-9-hour range is retained beside the 7-hour input for Trazodone. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 7 h as a representative input for Trazodone. In the simplified model, about 9.3% remains after 24 hours and about 3% remains after five half-lives, or roughly 35 h.
This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
antidepressant context
Antidepressant half-life values often need source context because parent compounds, active metabolites, enzyme interactions, and steady-state timing can all matter.
- Half-life is not a treatment-response timeline.
- Active metabolites can make parent-compound curves incomplete.
- Stopping, tapering, switching, or combining medications requires qualified medical guidance.
ComparisonTimeline checkpoints and nearby profiles
Trazodone timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 12 h | 30.5% | Long-tail portion of the model |
| 24 h | 9.29% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.86% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.08% | Low modeled remainder, not a clearance guarantee |
| 5.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Trazodone within the antidepressant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Bupropion (21 h)
- Venlafaxine (5 h)
- Sertraline (26 h)
- Escitalopram (30 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 7 h |
|---|---|
| Reported range | 6 h to 9 h |
| Curve type | Normalized, first-order decline |
Selection note: The seven-hour curve represents the later parent-trazodone elimination phase described in labeling context. Biphasic decline and the active mCPP metabolite mean that one line cannot describe every portion of exposure.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: TRAZODONE HYDROCHLORIDE TABLET [REMEDYREPACK INC.].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Trazodone.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Pharmacokinetics of Trazodone in Hispaniolan Parrots (Amazona ventralis).Non-human veterinary pharmacokinetic study; supplemental only because human labeling is also linked.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the antidepressant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.